Tonix Pharmaceuticals Holding (TNXP) Cash from Financing Activities (2010 - 2026)

Tonix Pharmaceuticals Holding has reported Cash from Financing Activities for 16 years, with the latest figure at $33.5 million in Q2 2026.

• On a quarterly basis, Cash from Financing Activities rose 204.78% year-over-year to $33.5 million in Q2 2026; TTM through Jun 2026 was $207.7 million, a 10.14% increase from a year earlier, with the FY2025 full-year figure at $214.5 million, up 59.06% from the prior year.
• Cash from Financing Activities was $33.5 million for Q2 2026 at Tonix Pharmaceuticals Holding, up from $20.2 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $94.9 million in Q3 2025, with the low at -$11.5 million in Q1 2023.
• Average Cash from Financing Activities over 5 years is $29.3 million, with a median of $16.6 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities plunged 188.03% in 2023, then surged 23464.62% in 2025.
• Over 5 years, Cash from Financing Activities stood at $7.2 million in 2022, then soared by 463.2% to $40.7 million in 2023, then surged by 109.15% to $85.2 million in 2024, then tumbled by 30.55% to $59.1 million in 2025, then sank by 43.35% to $33.5 million in 2026.
• The last three Cash from Financing Activities figures came in at $33.5 million (Q2 2026), $20.2 million (Q1 2026), and $59.1 million (Q4 2025), per Business Quant data.